Data published in the March issue of the Annals of Surgery show that investigational use of sacral nerve stimulation with Medtronic InterStim® Therapy reduces faecal incontinent episodes and increases quality of life in patients with the condition. The 120-
“InterStim Therapy has become an important treatment option for patients with overactive bladder who do not have success with more conservative therapies and a similar unmet clinical need exists for people living with faecal incontinence”
"Fecal incontinence is a debilitating and distressing condition, and current treatment options are limited," said Steven Wexner, M.D., professor and chair, Department of Colorectal Surgery at Cleveland Clinic Florida, first author of the published manuscript and lead investigator of the clinical trial. "The results of this study are promising and may provide a new treatment option for patients with faecal incontinence." Dr. Wexner is a paid consultant assisting Medtronic in the development of educational materials relating to this therapy. He assumed this role after the clinical study was completed.
Study participants were implanted with a Medtronic InterStim system to deliver mild electrical stimulation to the sacral nerves that control the bladder, sphincter and pelvic floor muscles. At 12 months of follow-
"InterStim Therapy has become an important treatment option for patients with overactive bladder who do not have success with more conservative therapies and a similar unmet clinical need exists for people living with faecal incontinence," said Tom Tefft, president of the Neuromodulation business and senior vice president at Medtronic. "Medtronic has been the pioneer and long-